No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ADMA ADMA Biologics
- 11.400
- -0.150-1.30%
Close Jul 2 16:00 ET
- 11.458
- +0.058+0.51%
Post 19:54 ET
2.64BMarket Cap-570000P/E (TTM)
11.680High11.340Low2.39MVolume11.530Open11.550Pre Close27.33MTurnover1.05%Turnover RatioLossP/E (Static)231.81MShares11.68052wk High17.19P/B2.60BFloat Cap3.06052wk Low--Dividend TTM227.80MShs Float14.000Historical High--Div YieldTTM2.94%Amplitude1.010Historical Low11.437Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
The 4.9% Return This Week Takes ADMA Biologics' (NASDAQ:ADMA) Shareholders Three-year Gains to 645%
For us, stock picking is in large part the hunt for the truly magnificent stocks. But when you hold the right stock for the right time period, the rewards can be truly huge. Take, for example, the A
Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know
Peeling Back The Layers: Exploring ADMA Biologics Through Analyst Insights
6 analysts have shared their evaluations of ADMA Biologics (NASDAQ:ADMA) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table provides a quick overv
ADMA Biologics Is Maintained at Buy by Mizuho
ADMA Biologics Is Maintained at Buy by Mizuho
ADMA Biologics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/20/2024 31.71% Mizuho $12 → $14 Maintains Buy 05/10/2024 -5.92% Raymond James $8 → $10 Maintains Strong
Mizuho Securities Maintains ADMA Biologics(ADMA.US) With Buy Rating, Raises Target Price to $14
Mizuho Securities analyst Anthony Petrone maintains $ADMA Biologics(ADMA.US)$ with a buy rating, and adjusts the target price from $12 to $14.According to TipRanks data, the analyst has a success rate
Comments
$ADMA Biologics(ADMA.US$
by the end of the year, what price will this stock reach? Any predictions?
by the end of the year, what price will this stock reach? Any predictions?
$ADMA Biologics(ADMA.US$
NEWS
IMPRESSIVE ER
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
ADMA Biologics reported impressive first quarter 2024 financial results, with a total revenue of $81.9 million, a 44% increase year-over-year. The GAAP net income was $17.8 million, a $24.6 million increase year-over-year. Adjusted EBITDA for Q1 2024 was $26.4 million, a 970% increase year-over-year. The company raised its total revenue guidance for FY 2024 to m...
NEWS
IMPRESSIVE ER
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
ADMA Biologics reported impressive first quarter 2024 financial results, with a total revenue of $81.9 million, a 44% increase year-over-year. The GAAP net income was $17.8 million, a $24.6 million increase year-over-year. Adjusted EBITDA for Q1 2024 was $26.4 million, a 970% increase year-over-year. The company raised its total revenue guidance for FY 2024 to m...
$ADMA Biologics(ADMA.US$
$Coinbase(COIN.US$
$Interactive Brokers(IBKR.US$
$Spotify Technology(SPOT.US$
so as much as it sucks apparently reason doesn't win, and here we are about to ban tiktok I guess? because something somethings china-boogeyman. It seems really foolish to upset millions of voters. let alone young voters. and besides their incredibly progressive leanings. I can't imagine what might backfire there.
That said. Between this and the fake news (like actually misinformation/sens...
$Coinbase(COIN.US$
$Interactive Brokers(IBKR.US$
$Spotify Technology(SPOT.US$
so as much as it sucks apparently reason doesn't win, and here we are about to ban tiktok I guess? because something somethings china-boogeyman. It seems really foolish to upset millions of voters. let alone young voters. and besides their incredibly progressive leanings. I can't imagine what might backfire there.
That said. Between this and the fake news (like actually misinformation/sens...
5
$ADMA Biologics(ADMA.US$
This one looks great. Solid fundamentals and technicals. VMACD shows golden cross, but reg macd still hasn't quite yet. Maybe a small dip coming but... worth it.
This one looks great. Solid fundamentals and technicals. VMACD shows golden cross, but reg macd still hasn't quite yet. Maybe a small dip coming but... worth it.
1
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg